How to Inject Melanotan II

What is Melanotan II?

Melanotan II is the peptide that wasn't supposed to be a sex drug. Norman Levine and colleagues at the University of Arizona melanoma research group developed it in the 1980s, hoping for a sunless tanning compound that could reduce skin cancer risk through MC1R-mediated melanogenesis. The clinical trials uncovered something nobody expected: dose-dependent erections in male subjects. That was the spinoff path that eventually produced PT-141 (bremelanotide). Melanotan II itself never got FDA approval — the Phase II trials had too many side effects to be viable as a tanning agent. But it survived in the grey market, where it's been sold as a research chemical for decades. National regulators and dermatologists actively warn against it because of melanoma concerns.

Mechanism

Melanotan II is a non-selective agonist of all four melanocortin receptors: MC1R, MC3R, MC4R, MC5R. That receptor promiscuity is both the source of its diverse effects and the reason its side effect profile is messy. MC1R activation in skin melanocytes drives eumelanin synthesis — that's the tanning effect. MC3R/MC4R activation in the hypothalamus drives appetite suppression and sexual arousal. MC4R activation triggers erections (the route to PT-141). MC5R activation modulates exocrine gland function. The key contrast: selective agonists like Setmelanotide (MC4R-selective) and Afamelanotide (MC1R-selective) avoid most of the off-target effects. Melanotan II hits everything at once.

Research Evidence

Tanning effects are well-documented in small trials — Dorr et al. (1996) at Arizona showed reproducible skin darkening responses. The sexual arousal observations led directly to PT-141's development as a targeted clinical candidate. The arm of the program targeting tanning never advanced past Phase II — the side effect profile (nausea, erections in male subjects, mole changes) was unworkable for a cosmetic indication. Long-term safety data is mostly absent except for case reports from grey-market use.

Dosing Considerations

Research protocols are 0.25-1 mg per dose subcutaneously, starting low and titrating up. The 'loading phase' approach uses small daily doses for 1-2 weeks until target pigmentation; 'maintenance phase' is 1-2 doses per week. Doses above 1 mg push the side effect rate up sharply. Evening dosing is common to minimize daytime side effects. Some sun exposure (UV from sunlight or a tanning bed) is needed to actually trigger the melanogenesis — Melanotan II by itself doesn't darken skin without UV stimulation.

Safety

Side effects: nausea (60-80% on first doses, dose-dependent), facial flushing, transient erections in male users (often unwanted), mole darkening and new mole formation (the headline melanoma concern), cardiovascular effects (heart rate, blood pressure changes), appetite suppression (welcome or unwelcome depending on user). The melanoma signal is the most concerning issue: case reports document new or accelerated melanomas in users; the mechanism is biologically plausible (MC1R activation in transformed melanocytes), but causation isn't established. Dermatologists strongly oppose Melanotan II use — any suspicious mole needs immediate evaluation.

Related Research Directions

Compounds often discussed alongside Melanotan II: melanotan-i, pt-141.

Related Research Compounds

If you're researching Melanotan II, the compounds you'll likely want to look at next are: MELANOTAN I, PT 141. These appear most often in the same research contexts as alternatives or complementary compounds.

References and Regulatory Notes

This guide synthesizes published research literature on Melanotan II. Specific citations are referenced inline where relevant. Research-compound regulatory status varies by jurisdiction; most are not approved by the FDA or equivalent agencies for human use and should be used only in research contexts compliant with applicable ethical review and regulations. This content is for research reference purposes only and does not constitute medical advice.